Tirofiban + Ticagrelor
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-ST Segment Elevation Acute Coronary Syndrome
Conditions
Non-ST Segment Elevation Acute Coronary Syndrome
Trial Timeline
Aug 1, 2012 → Aug 1, 2013
NCT ID
NCT01660373About Tirofiban + Ticagrelor
Tirofiban + Ticagrelor is a phase 3 stage product being developed by AstraZeneca for Non-ST Segment Elevation Acute Coronary Syndrome. The current trial status is unknown. This product is registered under clinical trial identifier NCT01660373. Target conditions include Non-ST Segment Elevation Acute Coronary Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01660373 | Phase 3 | UNKNOWN |
Competing Products
2 competing products in Non-ST Segment Elevation Acute Coronary Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ticagrelor + clopidogrel | AstraZeneca | Approved | 85 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |